[ CAS No. 20291-40-1 ] {[proInfo.proName]}

Name: 20291-40-1|7-Methoxy-7-oxoheptanoic acid|95%
Brand: Ambeed
SKU: A105938
Price: 19.0 USD
Availability: InStock
Rating: 90 (40 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 20291-40-1

Structure of 20291-40-1 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 20291-40-1 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 20291-40-1 ]

SDS Specification

Alternatived Products of [ 20291-40-1 ]

Product Details of [ 20291-40-1 ]

CAS No. :	20291-40-1	MDL No. :	MFCD00040445
Formula :	C₈H₁₄O₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	YOLQOHRXBGFZED-UHFFFAOYSA-N
M.W :	174.19	Pubchem ID :	88467
Synonyms :

Calculated chemistry of [ 20291-40-1 ]

Physicochemical Properties

Num. heavy atoms :	12
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.75
Num. rotatable bonds :	7
Num. H-bond acceptors :	4.0
Num. H-bond donors :	1.0
Molar Refractivity :	43.63
TPSA :	63.6 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.62 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.83
Log Po/w (XLOGP3) :	1.05
Log Po/w (WLOGP) :	1.19
Log Po/w (MLOGP) :	0.93
Log Po/w (SILICOS-IT) :	1.02
Consensus Log Po/w :	1.21

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-1.12
Solubility :	13.2 mg/ml ; 0.0759 mol/l
Class :	Very soluble
Log S (Ali) :	-1.98
Solubility :	1.84 mg/ml ; 0.0106 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.35
Solubility :	7.76 mg/ml ; 0.0446 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.58

Safety of [ 20291-40-1 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P264-P270-P272-P280-P301+P312+P330-P302+P352-P333+P313-P363-P501	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 20291-40-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 20291-40-1 ]

[ 20291-40-1 ] Synthesis Path-Downstream 1~88

1
[ 110-86-1 ]
[ 67-56-1 ]
[ 3878-55-5 ]
[ 54322-10-0 ]
[ 124-41-4 ]
[ 505-48-6 ]
[ 627-93-0 ]
[ 20291-40-1 ]

Reference： [1]Collection of Czechoslovak Chemical Communications,1954,vol. 19,p. 716

2
[ 111-16-0 ]
[ 1732-08-7 ]
[ 20291-40-1 ]

Yield	Reaction Conditions	Operation in experiment
68%	With hydrogenchloride; In methanol; ethyl acetate;	A. Methyl hydrogen pimelate (7) A mixture of pimelic acid (15) (75.1 g, 0.47 mol), <strong>[1732-08-7]dimethyl pimelate</strong> (50.1 g, 0.27 mol), hydrochloric acid (8 mL, 0.1 mol), methanol (25 mL, 0.62 mol) and di-n-butyl ether (20 mL) was heated (oil bath: 100-110 C.) under N2 overnight. After cooling to room temperature, EtOAc (200 mL) was added and the mixture was washed with water (2100 mL), saturated NaCl (2100 mL) and dried (Na2 SO4). The crude oil was fractionally distilled (vigreux, 125-130 C., 0.7 mm Hg) to provide a clear oil (55.5 g, 68%, purity?95%. Based on NMR analysis, the clear oil was determined to be methyl hydrogen pimelate (7) (1 H NMR)): TLC (SiO2, MeOH/EtOAc/hexane (2:8:15, v/v)) Rf =0.25-0.34; 1 H NMR (300 MHz, CDCl3) delta3.67 (s, 3 H), 2.40-2.28 (m, 4 H), 1.72-1.58 (m, 4 H), 1.45-1.32 (m, 2 H).

Reference： [1]Patent: US5952492,1999,A
[2]Chemische Berichte,1939,vol. 72,p. 455
[3]Journal of the Chemical Society. Perkin transactions I,1980,p. 2346 - 2352

3
[ 1732-08-7 ]
[ 20291-40-1 ]

Yield	Reaction Conditions	Operation in experiment
40%		General procedure: A solution of KOH (5.87 g, 104.65 mmol) in MeOH (150 ml) was added to dimethyl glutarate (13.15 g, 90 mmol), and the mixture was stirred for 4 h at rt. The solvent was then removed, and Et2O (100 ml) and H2O (200 ml) were added. The organic layer was separated, washed with brine, dried (MgSO4), and concentrated under reduced pressure to afford 3a as a yellow oil (4.61 g, 32%). The aqueous layer was acidified with concentrated HCl to pH 3, and extracted with Et2O (3 × 100 ml). The combined organic phase was washed with brine (3 × 100 ml) and dried (MgSO4). The solvent was removed to give a mixture of a white solid and an oil. Filtration and concentration in vacuum and purification with silica gel column chromatography gave 5.79 g (44%) of 4a as a colorless oil.
38%	With potassium hydroxide; In methanol; at 0 - 20℃; for 4h;	5.1.2 7-Methoxy-7-oxoheptanoic acid (84) A solution of KOH (5.87 g, 104.65 mmol) in CH3OH (150 ml) was added dropwise to <strong>[1732-08-7]dimethyl heptanedioate</strong> 82 (16.94 g, 90 mmol) at 0 C. The reaction mixture was allowed to be stirred for 4 h at room temperature. After removal of the solvent under reduced pressure, Et2O (100 ml) and H2O (200 ml) were added and the organic phase was concentrated to give 82 as yellow oil (5.08 g, 30%). The aqueous phase was acidified to pH 3 by concentrated HCl and extracted with Et2O (100 ml * 3). The combined organic layer was washed with brine (100 ml * 3) and dried over MgSO4. The solvent was concentrated in vacuum. Filtration and purification with silica gel column chromatography gave 5.96 g (38%) of compound 84 as colorless oil. ESI-MS m/z: 173.3 [M-H]-; 1H NMR (DMSO-d6) delta 1.23-1.31 (m, 4H), 1.44-1.57 (m, 4H), 2.19 (t, J = 7.2 Hz, 2H), 2.29 (t, J = 7.2 Hz, 2H), 3.58 (s, 3H), 11.97 (s, 1H). The synthetic procedures of compounds 85 were the same as that described above.

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1993,p. 1713 - 1714
[2]Tetrahedron Letters,2020,vol. 61
[3]Chemische Berichte,1983,vol. 116,p. 761 - 776
[4]Bioorganic and Medicinal Chemistry,2012,vol. 20,p. 3865 - 3872
[5]Bioorganic and Medicinal Chemistry,2014,vol. 22,p. 5766 - 5775
[6]Journal of the Chemical Society,1935,p. 290,291

4
[ 20291-40-1 ]
[ 35444-47-4 ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; for 1h;Reflux;	General procedure: A soln of 4a (1.46 g, 10 mmol) in SOCl2 (4 ml) was refluxed for 1 h. The SOCl2 was removed under reduced pressure to afford an orange oil, which was added dropwise to a stirred solution of 2a (1.42 g, 8 mmol) and Et3N (3.5 ml, 25 mmol) in anhydrous tetrahydrofuran (65 ml) at 0 C. The reaction mixture was allowed to be stirred overnight at room temperature. The solvent was removed in vacuum and the residue was diluted with dichloromethane (150 ml), washed with 1 M H3PO4 (3 × 80 ml) and brine (3 × 80 ml) and dried over with MgSO4. Filtration and concentration in vacuum and recrystallization from AcOEt gave 1.29 g of 5a as a white crystal.
	With thionyl chloride; In benzene; for 3h;Reflux;	General procedure: A solution of monomethyl alkanoic acid (n = 3-7) (1.2 eq) and thionyl chloride (1.4 eq) in benzene (5 mL) was refluxed for 3 h. Subsequently, the majority of the SOCl2 and benzene were removed by distillation. The mixture was cooled down to room temperature and dried under a vacuum to give a crude chlorocarbonyl-alkanoic acid methyl ester. A solution of chlorocarbonyl-alkanonic acid methyl ester in dichloromethane (5 mL) was added to a round flask containing 14 (1 eq) by cannula, and subsequently added pyridine (3.5 eq). The resulting solution was stirred at room temperature overnight, and quenched by adding water. The solution was extracted with ethyl acetate, dried (MgSO4), and evaporated to give a residue which was purified by column chromatography (Al2O3), eluting by ethyl acetate /hexane (1:15) to provide 15-19.
	With thionyl chloride; for 2h;Reflux;	5.1.3 Methyl 7-((5-(4-morpholinophenyl)-1,3,4-thiadiazol-2-yl)amino)-7-oxoheptanoate (86) A soln of 84 (1.74 g, 10 mmol) in SOCl2 (4 ml) was refluxed for 2 h. The removal of SOCl2 under reduced pressure yielded orange oil, which was dissolved in dichloromethane.

With oxalyl dichloride; In dichloromethane; N,N-dimethyl-formamide; at 20℃; for 4h;

General procedure: The oxalyl chloride (0.91 mL, 10.8 mmol) was added into thesolution of methyl 8-chloro-8-oxooctanoate (9, 680 mg, 3.6 mmol)and dry DMF (0.15 mL) in dry DCM (20 mL), then the mixturestirred at room temperature for 4 h. The excess oxalyl chloride andsolvent were evaporated under vacuum. The crude product (10) ofmonomethyl acid chloride was directly used for further reactionwithout any purification.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 1175 - 1180
[2]Journal of the Chemical Society. Perkin transactions I,1980,p. 2346 - 2352
[3]Tetrahedron Letters,1988,vol. 29,p. 6769 - 6772
[4]Liebigs Annalen der Chemie,1985,p. 1168 - 1174
[5]Journal of Medicinal Chemistry,1980,vol. 23,p. 981 - 985
[6]Patent: US6335443,2002,B1 .Location in patent: Page column 7
[7]Tetrahedron,1977,vol. 33,p. 1105 - 1112
[8]Chemische Berichte,1983,vol. 116,p. 761 - 776
[9]Journal of the Chemical Society. Chemical communications,1993,p. 410 - 412
[10]Journal of the Chemical Society. Perkin transactions I,1993,p. 2639 - 2650
[11]Bioorganic and Medicinal Chemistry,2012,vol. 20,p. 3865 - 3872
[12]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 5247 - 5250
[13]Bioorganic and Medicinal Chemistry,2014,vol. 22,p. 5766 - 5775
[14]Chemistry and Physics of Lipids,2014,vol. 184,p. 105 - 118
[15]Chemistry - A European Journal,2017,vol. 23,p. 3107 - 3116
[16]Tetrahedron Letters,2020,vol. 61
[17]European Journal of Medicinal Chemistry,2020,vol. 192
[18]Journal of the American Chemical Society,2021,vol. 143,p. 5166 - 5171
[19]Angewandte Chemie - International Edition,2021,vol. 60,p. 23743 - 23749
Angew. Chem.,2021,vol. 133,p. 23936 - 23942

5
[ 108-22-5 ]
[ 20291-40-1 ]
[ 148114-06-1 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1993,p. 2639 - 2650
[2]Journal of the Chemical Society. Chemical communications,1993,p. 410 - 412

6
[ 1112-02-3 ]
[ 20291-40-1 ]
[ 1632-99-1 ]
[ 106-70-7 ]
[ 1731-79-9 ]
C₈H₁₃⁽²⁾H₃O₂ [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1983,p. 543 - 551

7
[ 20291-40-1 ]
[ 19136-91-5 ]
[ 24330-31-2 ]
[ 106-70-7 ]
[ 1731-79-9 ]
C₉H₁₆⁽²⁾H₂O₂ [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1983,p. 543 - 551

8
[ 20291-40-1 ]
[ 136768-27-9 ]
[ 136768-26-8 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1991,p. 1981 - 1991

9
[ 20291-40-1 ]
[ 120167-80-8 ]
[ 1731-79-9 ]
[ 120167-89-7 ]
[ 120167-84-2 ]

Reference： [1]Bulletin de la Societe Chimique de France,1988,p. 571 - 578

10
[ 20291-40-1 ]
[ 120167-80-8 ]
[ 1731-79-9 ]
[ 120181-43-3 ]
[ 120167-85-3 ]

Reference： [1]Bulletin de la Societe Chimique de France,1988,p. 571 - 578

11
[ 20291-40-1 ]
[ 152575-82-1 ]
6-(4,5-Diphenyl-[2,4']bioxazolyl-5'-yl)-hexanoic acid methyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 3884 - 3903

12
[ 20291-40-1 ]
[ 502-44-3 ]

Reference： [1]Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry,1982,vol. 21,p. 329 - 330

13
[ 20291-40-1 ]
[ 24330-31-2 ]
[ 106-70-7 ]
[ 1731-79-9 ]
C₉H₁₆⁽²⁾H₂O₂ [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1983,p. 543 - 551

14
[ 20291-40-1 ]
[ 24330-31-2 ]
[ 2396-80-7 ]
[ 1731-79-9 ]
C₉H₁₆⁽²⁾H₂O₂ [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1983,p. 543 - 551

15
[ 20291-40-1 ]
[ 1731-79-9 ]
[ 120181-43-3 ]
[ 120167-85-3 ]

Reference： [1]Bulletin de la Societe Chimique de France,1988,p. 571 - 578

16
[ 20291-40-1 ]
[ 120-20-7 ]
[ 78632-03-8 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

17
[ 20291-40-1 ]
[ 75-05-8 ]
[ 83516-38-5 ]

Reference： [1]Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry,1982,vol. 21,p. 329 - 330

18
[ 20291-40-1 ]
[ 927-80-0 ]
[ 149142-48-3 ]
C₁₆H₂₆O₇ [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1993,p. 2999 - 3006

19
[ 20291-40-1 ]
[ 174501-66-7 ]
[ 174591-15-2 ]
2,3,4,6-Tetra-O-acetyl-1,5-anhydro-1-deoxy-1-C-ethyl-α-D-glucopyranose [ No CAS ]
2,3,4,6-Tetra-O-acetyl-1,5-anhydro-1-deoxy-1-C-<7-(methoxycarbonyl)heptyl>-α-D-glucopyranose [ No CAS ]

Reference： [1]Liebigs Annalen,1996,p. 55 - 62

20
[ 109-65-9 ]
[ 20291-40-1 ]
heptanedioic acid butyl ester methyl ester [ No CAS ]

Reference： [1]Tetrahedron Letters,2001,vol. 42,p. 9245 - 9248

21
[ 20291-40-1 ]
[ 100-39-0 ]
Heptanedioic acid benzyl ester methyl ester [ No CAS ]

Reference： [1]Tetrahedron Letters,2001,vol. 42,p. 9245 - 9248

22
[ 20291-40-1 ]
[ 193276-49-2 ]
methyl (+)-4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclo-hepta[1,2-b]pyridin-11(R)-yl)-ω-oxo-1-piperidinine-heptanoate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 139 - 143

23
[ 20291-40-1 ]
[ 193276-77-6 ]
[ 259528-12-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 139 - 143

24
[ 4971-56-6 ]
[ 20291-40-1 ]
[ 375374-83-7 ]

Reference： [1]Russian Journal of Organic Chemistry,2003,vol. 39,p. 998 - 1009

25
[ 20291-40-1 ]
[ 84465-82-7 ]
[ 662151-98-6 ]

Reference： [1]Russian Journal of Organic Chemistry,2003,vol. 39,p. 998 - 1009

26
[ 20291-40-1 ]
[ 5457-19-2 ]
[ 662151-96-4 ]

Reference： [1]Russian Journal of Organic Chemistry,2003,vol. 39,p. 998 - 1009

27
[ 20291-40-1 ]
[ 209608-44-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 1175 - 1180

28
[ 20291-40-1 ]
[ 209608-43-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 1175 - 1180

29
[ 20291-40-1 ]
6-{3-[4-Bromo-2-(3-chloro-propionylamino)-phenylsulfanyl]-phenylcarbamoyl}-hexanoic acid methyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 1175 - 1180

30
[ 20291-40-1 ]
[ 209608-46-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 1175 - 1180

31
[ 20291-40-1 ]
6-(3-{4-Bromo-2-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylsulfanyl}-phenylcarbamoyl)-hexanoyl fluoride [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 1175 - 1180

32
[ 20291-40-1 ]
[ 209608-45-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 1175 - 1180

33
[ 20291-40-1 ]
6-(4,5-Diphenyl-[2,4']bioxazolyl-5'-yl)-hexanoic acid [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 3884 - 3903

34
[ 20291-40-1 ]
[ 148114-12-9 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1993,p. 2639 - 2650
[2]Journal of the Chemical Society. Perkin transactions I,1993,p. 2639 - 2650
[3]Journal of the Chemical Society. Chemical communications,1993,p. 410 - 412
[4]Journal of the Chemical Society. Chemical communications,1993,p. 410 - 412

35
[ 20291-40-1 ]
[ 148114-10-7 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1993,p. 2639 - 2650
[2]Journal of the Chemical Society. Perkin transactions I,1993,p. 2639 - 2650
[3]Journal of the Chemical Society. Perkin transactions I,1993,p. 2999 - 3006
[4]Journal of the Chemical Society. Chemical communications,1993,p. 410 - 412
[5]Journal of the Chemical Society. Chemical communications,1993,p. 410 - 412

36
[ 20291-40-1 ]
3'-N-(6-carboxy-1-oxohexyl)oxaunomycin [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1993,p. 2999 - 3006

37
[ 20291-40-1 ]
methyl phenethyl pimelate [ No CAS ]

38
[ 20291-40-1 ]
[ 56188-28-4 ]

Reference： [1]Journal of Medicinal Chemistry,1980,vol. 23,p. 981 - 985

39
[ 20291-40-1 ]
[ 74509-52-7 ]

Reference： [1]Journal of Medicinal Chemistry,1980,vol. 23,p. 981 - 985

40
[ 20291-40-1 ]
3,6-Epoxytridecandisaeure-dimethylester [ No CAS ]

Reference： [1]Liebigs Annalen der Chemie,1985,p. 1168 - 1174

41
[ 20291-40-1 ]
[ 78632-07-2 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

42
[ 20291-40-1 ]
[ 78631-97-7 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

43
[ 20291-40-1 ]
[ 78632-02-7 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

44
[ 20291-40-1 ]
[ 78631-96-6 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

45
[ 20291-40-1 ]
[ 78632-01-6 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

46
[ 20291-40-1 ]
[ 78632-04-9 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

47
[ 20291-40-1 ]
[ 78632-17-4 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

48
[ 20291-40-1 ]
[ 78632-19-6 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

49
[ 20291-40-1 ]
[ 78632-18-5 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 2158 - 2185

50
[ 20291-40-1 ]
[ 35376-00-2 ]

Reference： [1]Tetrahedron Letters,1988,vol. 29,p. 6769 - 6772

51
[ 20291-40-1 ]
[ 76822-56-5 ]

Reference： [1]Tetrahedron Letters,1988,vol. 29,p. 6769 - 6772

52
[ 20291-40-1 ]
[ 125151-77-1 ]

Reference： [1]Tetrahedron Letters,1988,vol. 29,p. 6769 - 6772

53
[ 20291-40-1 ]
[ 122804-45-9 ]

Reference： [1]Tetrahedron Letters,1988,vol. 29,p. 6769 - 6772

54
[ 20291-40-1 ]
7-{(2R,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(3R,4R)-3-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-4-methyl-oct-1-enyl]-5-oxo-cyclopentyl}-7-hydroxy-heptanoic acid methyl ester [ No CAS ]

Reference： [1]Tetrahedron Letters,1988,vol. 29,p. 6769 - 6772

55
[ 67-56-1 ]
[ 111-16-0 ]
[ 1732-08-7 ]
[ 20291-40-1 ]

Reference： [1]Patent: US6335443,2002,B1 .Location in patent: Page column 7

56
[ 79-37-8 ]
1-methyl-3-nitro-1-nitrosoquanidine [ No CAS ]
[ 20291-40-1 ]
[ 436152-30-6 ]

Yield	Reaction Conditions	Operation in experiment
85%	With aqueous KOH; conc. HBr; In diethyl ether; dichloromethane; N,N-dimethyl-formamide;	Example 196A methyl 8-bromo-7-oxooctanoate A solution of <strong>[20291-40-1]7-methoxy-7-oxoheptanoic acid</strong> (4.6 g, 26.6 mmol) in dichloromethane at room temperature (200 mL) was treated with oxalyl chloride (2.55 mL) and 1 drop of DMF, stirred for 1 hour, concentrated, and dissolved in diethyl ether (2 mL) to provide solution A. A mixture of diethyl ether (150 mL) and 40% aqueous KOH (45 mL) at 0 C. was treated portionwise with 1-methyl-3-nitro-1-nitrosoquanidine (15 g), and stirred for 10 minutes. The organic phase was dried over KOH, filtered, cooled to 0 C., treated with solution A, stirred at 0 C. for 1.5 hours, treated with conc. HBr (33 mL), warmed to room temperature, and stirred for 30 minutes. The reaction was partitioned between water and ethyl acetate and the organic phase was washed with saturated NaHCO3, dried (Na2SO4), filtered and concentrated to provide 5.69 g (85% yield) of the desired product. MS (DCI) m/e 268, 270 (M+NH4)+.

Reference： [1]Patent: US2002/177594,2002,A1

57
[ 20291-40-1 ]
[ 33513-42-7 ]
[ 53367-58-1 ]

Yield	Reaction Conditions	Operation in experiment
92%	With thionyl chloride;	B. Methylpimeloyl chloride (8) Fifty three grams (53 g) of methyl hydrogen pimelate (7) (0.3 mol) from A above was mixed with thionyl chloride (30 mL, 0.4 mol) and dimethyl formamide (0.3 mL) were stirred with heating overnight (oil bath: 52 C.). The excess thionyl chloride was then removed by distillation. The crude oil which resulted was distilled (0.6 mm Hg, 80-90 C.) to provide a clear oil (54.1 g, 92%, purity≅95%. Based on NMR analysis, the clear oil was determined to be methylpimeloyl chloride (8) (1 H NMR)): 1 H NMR (300 MHz, CDCl3) δ3.67 (s, 3 H), 2.90 (t, J=7.8 Hz, 2 H), 2.33 (t, J=7.3 Hz, 2 H), 1.80-1.60 (m, 4 H), 1.45-1.30 (m, 2 H).

Reference： [1]Patent: US5952492,1999,A

58
[ 20291-40-1 ]
[ 64-04-0 ]
[ 530-62-1 ]
[ 119627-44-0 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; sodium hydroxide; In methanol; dichloromethane; ethyl acetate;	(j) 7-Oxo-7-[2-phenylethylamino]heptanoic acid A solution of monomethylpimelate (5.0 g) and N,N-carbonyldiimidazole (4.9 g) in dry dichloromethane (200 ml) was stirred under nitrogen at 20 for 2 hours and a solution of 2-phenylethylamine (3.22 g) in dry dichloromethane (100 ml) was then added. The mixture was stirred at 20 for 16 hours. The solution was quenched with 2N hydrochloric acid (50 ml) and separated. The organic solution was washed with water, dried (MgSO4), filtered and evaporated to leave the intermediate ester as a solid (7.05 g). A solution of the ester (7.0 g) in methanol (100 ml) and 20% sodium hydroxide solution (15 ml) was heated to reflux temperature for 3 hours. The solution was evaporated and the residue acidified with 2N hydrochloric acid. The solid mass was dissolved in ethyl acetate (400 ml), washed with water (2*100 ml), dried (MgSO4), filtered and evaporated. Crystallisation from ethyl acetate gave the sub-title acid intermediate as colourless prisms (5.7 g), mp 78-79.

Reference： [1]Patent: US4922022,1990,A

59
[ 79-37-8 ]
1-hydroxy-2-naphthylhydroxylamine hydrochloride [ No CAS ]
[ 20291-40-1 ]
N-hydroxy-N-(1-hydroxy-2-naphthyl)-6-methoxycarbonylhexanamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
738 mg (78%)	With triethylamine; In tetrahydrofuran; dichloromethane; water; N,N-dimethyl-formamide;	EXAMPLE 3-5 Synthesis of N-hydroxy-N-(1-hydroxy-2-naphthyl)-6-methoxycarbonylhexanamide STR71 Into a 25 ml methylene chloride solution of 500 mg (2.87 mmol) of <strong>[20291-40-1]6-methoxycarbonylhexanoic acid</strong> and 222 μl (2.87 mmol) of DMF was added 564 μl (6.46 mmol) of oxalyl chloride at 0 C., and the mixture was stirred as such for one hour. The mixture was then added to a solution of 3.17 g (15 mmol) of 1-hydroxy-2-naphthylhydroxylamine hydrochloride, 3.1 ml (23 mmol) of triethylamine in THF (25 ml), and water (5 ml), at 0 C., and after stirring at 0 C. for one hour and at room temperature for one hour, the reaction was completed with aqueous KHSO4, and the mixture was extracted with methylene chloride. The organic layer was washed with 4N HCl and with saturated aqueous NaCl, and then dried over anhydrous magnesium sulfate, and after evaporation of the solvent under a reduced pressure, the residue was subjected to silica gel column chromatography to give 738 mg (78%) of the desired product. NMR (δ ppm, CDCl3) 1.2-2.0 (m, 6H), 2.25-2.6 (m, 4H), 3.7 (s, 3H), 7.05 (d, 1H, J=9 Hz), 7.2-8.0 (m, 5H), 8.4 (m, 1H), 9.7 (m, 1H)

Reference： [1]Patent: US5149859,1992,A

60
[ 20291-40-1 ]
[ 95-55-6 ]
[ 1318075-04-5 ]

Reference： [1]Angewandte Chemie - International Edition,2007,vol. 46,p. 7960 - 7964

61
[ 20291-40-1 ]
[ 541-41-3 ]
[ 339578-95-9 ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine; In dichloromethane; at 0℃; for 2h;	To a solution of monomethyl ester monoacid (11mmol) in methylene chloride (50mL) was added N-methyl morpholine (1.4mL, 13mmol) followed by ethyl chloroformate (0.95mL, 10mmol). After the solution was stirred at 0 C for 2h, orthoaminoanilide (982mg, 9mmol) and N-methylmorpholine (1.4mL, 13mmol) were added at 0 C. The solution was stirred at room temperature for 8h. The resulting solution was diluted with ethyl acetate and was washed with water. The organic layer was dried over magnesium sulfate and evaporated under vacuum. Flash chromatography on silica gel eluting with 30-50% ethyl acetate in pet ether afforded the monomethyl ester orthohydroxyanilide.To a solution of monomethyl ester ortho-hydroxyanilide (6.2mmol) in methanol (20mL) was added hydrazine (0.8mL, 24.8mmol) at room temperature. The solution was stirred at 60 C for 48h. White precipitate appeared after the solution was cooled to 0 C. The crudesolid product was collected by filtration after washing with cold ethanol and pet ether.Flash chromatography on a short silica gel column eluting with 5-10% methanol in methylene chloride afforded final product.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 2601 - 2605

62
[ 67-56-1 ]
pimelic acid polyanhydride [ No CAS ]
[ 20291-40-1 ]

Yield	Reaction Conditions	Operation in experiment
34%	With dmap; In dichloromethane; at 20℃;	General procedure: The solution of an alcohol, the corresponding polyanhydride or monoanhydride of dicarboxylic acid and DMAP (0.02 g) in CH2Cl2 was stirred at room temperature for 24-48 h. The mixture was evaporated under reduced pressure and the residue was purified by column chromatography in the gradient mixture ethyl acetate/petroleum ether (1:5 ÷ 1:1).

Reference： [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 5529 - 5538

63
[ 20291-40-1 ]
[ 3476-50-4 ]
[ 1338797-78-6 ]

Yield	Reaction Conditions	Operation in experiment
57.8%	With triethylamine; O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluroniumhexafluorophosphate; In dichloromethane; for 2h;	General procedure: Desacetylcolchicine (200 mg, 0.56 mmol), the chosen acid(0.62 mmol), HATU (213 mg, 0.56 mmol), and triethylamine(113 mg, 1.12 mmol) were stirred in 5 mL DCM for 2 h. The mixturewas washed with 10% citric acid followed by brine and thenconcentrated in vacuo. The crude product was purified by columnchromatography.
41%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In dichloromethane; at 20℃; for 60h;	General procedure: The solution of dicarboxylic acid mono-ester in CH2Cl2, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) and N-deacetylcolchicine were stirred together at room temperature for 12-60 h. The mixture was concentrated and the residue was purified by column chromatography.

Reference： [1]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 3240 - 3244
[2]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 5529 - 5538

64
[ 20291-40-1 ]
[ 1133966-20-7 ]
[ 1133966-21-8 ]

Yield	Reaction Conditions	Operation in experiment
78%	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 123℃; for 6h;Inert atmosphere;	Step 11b. (E)-Methyl 7-oxo-7-(2-(3-(2-(pyridin-2-yl)vinyl)-lH-indazol-6-ylthio) phenylamino)heptanoate (Compound 308-11) To a mixture of compound 307-11 (75.5 mg, 0.22 mmol), EDCI (0.36 g, 1.9 mmol) in DMF ( 0.2 mL ) were added <strong>[20291-40-1]7-methoxy-7-oxoheptanoic acid</strong> (0.12 g, 0.66mmol ) and DMAP ( 0.23 g, 1.9 mmol ) . The mixture was stirred at 123 0C for 6 hours under nitrogen. After removed most of solvent under reduced pressure, the residue was partitioned with ethyl acetate and water. The organic phase was separated and washed with water, brine, dried over anhydrous Na2SO4, filtered and evaporated to afford the title compound 308-11 as a pale yellow solid (100 mg, 78 %): LCMS: 585 (M+l); 1H NMR (DMSO-d6): δ 1.09-1.17 (m, 4 H), 1.32-1.42 (m, 6 H), 2.12-2.17 (t, J= 7.2 Hz,2 H), 2.19-2.24 (t, J= 7.5 Hz, 2 H), 3.51 (s, 3 H), 7.05- 7.08 (d, J= 7.2 Hz, 1 H), 7.19-7.29 (m, 3 H), 7.38-7.44 (m, 2 H), 7.50-7.56 (d, J = 15.9 Hz, 1 H), 7.63-7.72 (m, 2 H), 7.80-7.82 (m, 1 H), 7.88-7.93 (t, J= 16.5, 1 H), 8.12-8.15 (d, J= 8.7 Hz,l H), 8.59-8.60 (d, J= 3.6 Hz,l H), 9.40 (s, I H), 13.19 (s, I H).

Reference： [1]Patent: WO2009/36066,2009,A1 .Location in patent: Page/Page column 67

65
[ 20291-40-1 ]
methyl 7-(1-ethoxy-1-oxopropan-2-ylamino)-7-oxoheptanoate [ No CAS ]

Reference： [1]Organic Letters,2013,vol. 15,p. 2530 - 2533

66
[ 20291-40-1 ]
[ 1432740-99-2 ]

Reference： [1]Organic Letters,2013,vol. 15,p. 2530 - 2533

67
[ 20291-40-1 ]
[ 118399-97-6 ]

Reference： [1]Organic Letters,2013,vol. 15,p. 2530 - 2533

68
[ 20291-40-1 ]
[ 543-27-1 ]
C₁₃H₂₂O₆ [ No CAS ]

Reference： [1]Organic Letters,2013,vol. 15,p. 2530 - 2533

69
[ 20291-40-1 ]
[ 775302-21-1 ]
[ 1620517-26-1 ]

Yield	Reaction Conditions	Operation in experiment
61%	With 3-Methylpyridine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 24h;	In an ice-water bath, to a mixture of 8 (0.25g, 1mmol), EDC (0.4g), HOBt (0.3g) and monomethyl heptanedioate (17b, 0.15g) in DCM (10mL) was added 3-picoline (0.3mL), and after stirring for 24h, the reaction solution was diluted by DCM (20mL) and methanol (8mL). The organic solution was washed by 5% HCl, 5% NaOH and saturated NaHCO3 successively, dried over anhydrous Na2SO4, and then purified by column chromatography (DCM/EtOAc=10/1) to give 17a as a white solid (0.25g, yield: 61%). 17a was reduced by NaBH4 by a procedure similar to that for the preparation of 14 to give 17 as a white solid.

Reference： [1]European Journal of Medicinal Chemistry,2014,vol. 83,p. 15 - 25

70
[ 20291-40-1 ]
[ 1394329-62-4 ]
C₂₈H₃₂N₄O₅ [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 239 - 243

71
[ 20291-40-1 ]
[ 1197159-91-3 ]
C₂₅H₃₄N₆O₅ [ No CAS ]

Reference： [1]Bulletin of the Korean Chemical Society,2016,vol. 37,p. 42 - 47

72
[ 20291-40-1 ]
[ 52568-28-2 ]
C₁₅H₂₂N₂O₃ [ No CAS ]

Reference： [1]Synlett,2016,vol. 27,p. 2396 - 2400

73
[ 20291-40-1 ]
[ 52568-28-2 ]
C₁₆H₂₄N₂O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: To a round bottom flask was added the acid (5 mmol) and dry CH2Cl2 (20 mL). Thenthe flask was submerged in a brine ice bath, N-methylmorpholine (6 mmol) was addedvia syringe and the solution stirred for 15 min. After that, isobutylchloroformate (5.5mmol) was added dropwise over 20 minutes. After stirring for 6 h at ambienttemperature, the resulting mixture was washed with sat. Na2CO3, and brine, dried overMgSO4, filtered and concentrated under reduced pressure. The residue was purified byflash chromatography to give the desired product

Reference： [1]Synlett,2016,vol. 27,p. 2396 - 2400

74
[ 41796-82-1 ]
[ 124-38-9 ]
[ 20291-40-1 ]
[ 73891-59-5 ]

Yield	Reaction Conditions	Operation in experiment
	With nickel(II) iodide; manganese; 2,9-dihexyl-4,7-diphenyl-1,10-phenanthroline; In N,N-dimethyl-formamide; at 38℃; under 760.051 Torr;	Table 8: Scope of temperatureIn Entries 56-61:(i)the compound of formula (I) is that wherein R1 and R1’are phenyl and R2 and R2’ are n-hexyl(entry 36), and its amount is 4.40 mol%;(ii) the nickel (II) salt is nickel (II) iodide and its amount is 2.5 mol%;(iii) the reducing agent is manganese and its amount is 3.0 times the amount of methyl 5-bromohexanoate engaged in the reaction;(iv) the solvent is DMF;(vi) the temperature is as indicated in Table 8.
	With nickel(II) iodide; manganese; 2,9-dihexyl-4,7-diphenyl-1,10-phenanthroline; In N,N-dimethyl-formamide; at 10℃; under 760.051 Torr;	General procedure: Table 8: Scope of temperatureIn Entries 56-61:(i)the compound of formula (I) is that wherein R1 and R1’are phenyl and R2 and R2’ are n-hexyl(entry 36), and its amount is 4.40 mol%;(ii) the nickel (II) salt is nickel (II) iodide and its amount is 2.5 mol%;(iii) the reducing agent is manganese and its amount is 3.0 times the amount of methyl 5-bromohexanoate engaged in the reaction;(iv) the solvent is DMF;(vi) the temperature is as indicated in Table 8.
	With nickel(II) iodide; manganese; 2,9-dihexyl-4,7-diphenyl-1,10-phenanthroline; In N,N-dimethyl-formamide; at 42℃; under 760.051 Torr;	General procedure: Table 8: Scope of temperatureIn Entries 56-61:(i)the compound of formula (I) is that wherein R1 and R1’are phenyl and R2 and R2’ are n-hexyl(entry 36), and its amount is 4.40 mol%;(ii) the nickel (II) salt is nickel (II) iodide and its amount is 2.5 mol%;(iii) the reducing agent is manganese and its amount is 3.0 times the amount of methyl 5-bromohexanoate engaged in the reaction;(iv) the solvent is DMF;(vi) the temperature is as indicated in Table 8.

Reference： [1]Nature,2017,vol. 545,p. 84 - 88
[2]Nature,2017,vol. 545,p. 84 - 88
[3]Patent: WO2018/10932,2018,A1 .Location in patent: Page/Page column 64
[4]Patent: WO2018/10932,2018,A1 .Location in patent: Page/Page column 64; 65
[5]Patent: WO2018/10932,2018,A1 .Location in patent: Page/Page column 64; 65

75
[ 124-38-9 ]
[ 78019-66-6 ]
[ 20291-40-1 ]
[ 73891-59-5 ]

Reference： [1]Nature,2017,vol. 545,p. 84 - 88
[2]Nature,2017,vol. 545,p. 84 - 88

76
[ 14273-90-6 ]
[ 124-38-9 ]
[ 20291-40-1 ]
[ 73891-59-5 ]

Reference： [1]Nature,2017,vol. 545,p. 84 - 88

77
[ 14273-90-6 ]
[ 124-38-9 ]
[ 20291-40-1 ]

Reference： [1]Nature,2017,vol. 545,p. 84 - 88

78
[ 20291-40-1 ]
(5-aminoindolin-1-yl) (2,4-bis(benzyloxy)-5-isopropylphenyl)methanone [ No CAS ]
methyl 7-((1-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)indolin-5-yl)amino)-7-oxoheptanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
74%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 5h;Inert atmosphere;	General procedure: A mixture of S-2 (0.3 g, 0.609 mmol), EDC.HCl (0.232 g, 1.21 mmol), HOBt (0.123 g,737 mg, 0.914 mmol), 4-methoxy-4-oxobutanoic acid (0.96 g, 0.727 mmol) and DIPEA(0.265 mL, 1.52 mmol) in DMF (5 mL) was stirred at rt for 5 h. After being stirred fora further 5 h, the reaction mixture was quenched with H2O and extracted with EtOAc(50 mL 3). The combined organic layer was dried over anhydrous MgSO4, concentratedunder reduced pressure and purified by silica gel chromatography (hexane:EtOAc = 4:1) togive S-3 in 80% yield;
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 10h;	General procedure: A mixture of 18(0.3 g,0.609 mmol), EDC. HCl (0.232 g, 1.21 mmol), HOBt (0.123 g, 737 mg,0.914 mmol), 4-methoxy-4-oxobutanoic acid (0.96 g, 0.727 mmol)and DIPEA (0.265 mL, 1.52 mmol) in DMF (5 mL) was stirred at rt for5 h. After being stirred for a further 5 h, the reaction mixture was quenched with H2O and extracted with EtOAc (50 mL x 3). Thecombined organic layer was dried over anhydrous MgSO4,concentrated under reduced pressure and purified by silica gelchromatography (hexane: EtOAc 4:1) to give 19 in 80% yield.

Reference： [1]Molecules,2021,vol. 26
[2]European Journal of Medicinal Chemistry,2018,vol. 150,p. 667 - 677

79
[ 20291-40-1 ]
[ 106-50-3 ]
methyl 7-((4-aminophenyl)amino)-7-oxoheptanoate [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 3166 - 3192

80
[ 20291-40-1 ]
[ 1204669-57-7 ]
C₂₁H₂₄BrFN₆O₆ [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 312 - 317

81
[ 20291-40-1 ]
[ 31938-11-1 ]
C₂₆H₂₇NO₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
63.75%		General procedure: A mixture of corresponding mono-substituted dioic acid (1.0 eq), O-(triphenylmethyl) hydroxylamine (1.0 eq), T3P (0.6 eq), TEA (2.5 eq)was dissolved in DCM, and stirring at room temperature for overnight.The reaction was quenched by water, and extracted with DCM. After washed with and NaHCO3 and concentrated to dryness. The crudeproduct was dissolved in THF, LiOH·H2O (5.0 eq) and water were addedto the solution. The mixture was stirred at room temperature forovernight. After regulated pH to acid, extracted with EA, the organiclayer was washed by brine and dried over Na2SO4. The final productwas purified by silica gel column to afford a white powder. 4.2.1.1. Compound 7a. Starting from 6a, and 7a was afforded as awhite solid (1.53 g, 63.75%). 1H NMR (400 MHz, DMSO-d6) δ 11.98 (s,1H), 10.18 (s, 1H), 7.32 (d, J=10.5 Hz, 15H), 2.10 (t, J=7.4 Hz, 2H),1.78 (t, J=6.9 Hz, 2H), 1.34 (dd, J=14.5, 7.3 Hz, 2H), 1.20 (dt,J=14.1, 5.0 Hz, 2H), 0.98 (d, J=6.8 Hz, 2H). MS (ESI) m/z=418.20[M+H]+.

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 4706 - 4715

82
[ 20291-40-1 ]
[ 1092522-02-5 ]
C₂₀H₃₀N₂O₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 12h;	General procedure: HBTU (1.82g, 3.59mmol), DIPEA (0.84mL, 4.80mmol) and monomethyl suberate (0.93mL, 5.28mmol) were added to a solution of 34 (1.0g, 4.80mmol) in DMF (10mL) and the mixture was stirred for 12hat rt. Then the reaction was quenched with H2O and extracted using EtOAc, dried over MgSO4 and passed through a filter column to give corresponding ester which was dissolved in the minimum amount of dioxane. H2O with pH adjusted to 3 using 3N HCl was added and the reaction mixture was stirred at reflux overnight to yield the corresponding free amine. The reaction was basified and extracted using EtOAc, then dried, concentrated and passed through a filter column to give the free amine. To a solution of this free amine (1.0g, 3.59mmol) in DMF (10mL) was added HBTU (1.36g, 3.59mmol), DIPEA (0.66mL, 3.59mmol) and 1,4-dibenzyloxy-5-isopropyl benzoic acid (0.76g, 4.31mmol) and the solution was stirred for 12hat 80C. The reaction mixture was quenched with H2O and extracted with EtOAc (25mL×3). The combined organic layer was collected, dried over anhydrous MgSO4 and concentrated under reduced pressure to give a light yellow residue, which was purified by silica gel chromatography (EtOAc:n-hexane=1: 1) to give 42 as a colorless liquid in 65% yield (overall from 34)

Reference： [1]Patent: WO2018/171575,2018,A1 .Location in patent: Page/Page column 31; 33; 35
[2]European Journal of Medicinal Chemistry,2020,vol. 185

83
[ 527750-17-0 ]
[ 20291-40-1 ]
C₂₇H₃₃NO₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
73%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;	Amino compound (2.5 g, 7.5 mmol) was dissolved in 10 ml of anhydrous N, N-dimethylformamide, 1.2 equivalent of <strong>[20291-40-1]monomethyl pimelate</strong> was added, and twice the amount was added with stirring. HATU and four times the amount of N,N-diisopropylethylamine; the mixture was stirred at room temperature overnight, saturated brine was added, and extracted three times with ethyl acetate.The sodium was dried, and the crude product was purified by column chromatography, and the mobile phase was ethyl acetate: petroleum ether = 1:3 to obtain pure product, the yield was 73%

Reference： [1]Patent: CN109651199,2019,A .Location in patent: Paragraph 0111; 0116; 0120

84
[ 20291-40-1 ]
Didemethylclomipramine [ No CAS ]
methyl 7-((3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)amino)-7-oxoheptanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 5h;	General procedure: A mixture of compound 19 (350 mg, 1.22 mmol), EDCHCl(467 mg, 2.4 mmol), HOBt (250 mg, 1.85 mmol), DIPEA (0.46 mL,3 mmol) in DMF (3 mL) and 4-methoxy-4-oxobutanoic acid(230 mg, 1.7 mmol) was stirred at rt for 5 h. The reaction mixturewas quenched with H2O and extracted with EtOAc (50 mL x 3). Thecombined organic layer was dried over anhydrous MgSO4,concentrated under reduced pressure and purified by silica gelchromatography (EtOAc:Hexane 1:1) to give 20 in 84% yield.

Reference： [1]European Journal of Medicinal Chemistry,2020,vol. 187

85
[ 20291-40-1 ]
[ 913000-10-9 ]
methyl 7-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl) amino)-7-oxoheptanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
79%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 5h;	General procedure: A mixture of 22 (0.3 g, 0.609 mmol), EDC.HCl (0.232 g,1.21 mmol), HOBt (0.123 g, 737 mg, 0.914 mmol), 4-methoxy-4-oxobutanoic acid (0.96 g, 0.727 mmol) and DIPEA (0.265 mL,1.52 mmol) in DMF (5 mL) was stirred at rt for 5 h. After being stirred for a further 5 h, the reaction mixture was quenched withH2O and extracted with EtOAc (50 mL x 3). The combined organiclayer was dried over anhydrous MgSO4, concentrated underreduced pressure and purified by silica gel chromatography (hexane:EtOAc 4 : 1) to give 25 in 80% yield;

Reference： [1]European Journal of Medicinal Chemistry,2020,vol. 190

86
[ 20291-40-1 ]
C₂₂H₂₅N₃O₄ [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2020,vol. 192

87
[ 20291-40-1 ]
C₂₁H₂₃N₃O₄ [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2020,vol. 192

88
[ 20291-40-1 ]
C₂₀H₂₆BrN₃O₅ [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2020,vol. 192

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 20291-40-1 ]

Aliphatic Chain Hydrocarbons

[ 34957-73-8 ]

Methyl 9-hydroxynonanoate

Similarity: 1.00

[ 627-91-8 ]

Monomethyl adipate

Similarity: 1.00

[ 1731-92-6 ]

Methyl heptadecanoate

Similarity: 1.00

[ 818-88-2 ]

10-Methoxy-10-oxodecanoic acid

Similarity: 1.00

[ 111-11-5 ]

Methyl octanoate

Similarity: 1.00

Esters

[ 34957-73-8 ]

Methyl 9-hydroxynonanoate

Similarity: 1.00

[ 627-91-8 ]

Monomethyl adipate

Similarity: 1.00

[ 1731-92-6 ]

Methyl heptadecanoate

Similarity: 1.00

[ 818-88-2 ]

10-Methoxy-10-oxodecanoic acid

Similarity: 1.00

[ 111-11-5 ]

Methyl octanoate

Similarity: 1.00

Carboxylic Acids

[ 3903-40-0 ]

12-Methoxy-12-oxododecanoic acid

Similarity: 1.00

[ 627-91-8 ]

Monomethyl adipate

Similarity: 1.00

[ 818-88-2 ]

10-Methoxy-10-oxodecanoic acid

Similarity: 1.00

[ 2104-19-0 ]

Monomethyl Azelate

Similarity: 1.00

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 20291-40-1 ] {[proInfo.proName]}

Quality Control of [ 20291-40-1 ]

Related Doc. of [ 20291-40-1 ]

Product Details of [ 20291-40-1 ]

Calculated chemistry of [ 20291-40-1 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 20291-40-1 ]

Application In Synthesis of [ 20291-40-1 ]

[ 20291-40-1 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 20291-40-1 ]

Aliphatic Chain Hydrocarbons

Esters

Carboxylic Acids

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 20291-40-1 ]